Abstracts tagged "Lupus nephritis"

Abstract Number: 0334 • ACR Convergence 2022
Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records
Zara Izadi¹, Alfredo Aguirre², Christine Anastasiou², Julia Kay³, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵UCSF, San Rafael, CA
Background/Purpose: Real-world data could provide valuable information in the study of lupus nephritis (LN), if these cases could be reliably identified. A lack of ability…
Abstract Number: 0630 • ACR Convergence 2022
Ferroptosis of CD163+ Tissue Infiltrating Macrophages in Lupus Nephritis
Qi Cheng, Huaxiang Wu and Yan Du, The Second Affiliated Hospital Of Zhejiang University School Of Medicine, Hangzhou, China
Background/Purpose: Lupus nephritis (LN) is one of the most common complications of systemic lupus erythematosus (SLE), with high morbidity and mortality. Despite a better understanding…
Abstract Number: 1135 • ACR Convergence 2022
Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
Shudan Wang¹, Anna Broder², Daming Shao³, Vartika Kesarwani⁴, Brianna Lally⁵, Masako Suzuki⁶, J. Michelle Kahlenberg⁷, Jennifer Aguilan⁶ and Simone Sidoli⁶, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Hackensack University Medical Center, Hackensack, NJ, ³Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴University of Connecticut, Farmington, CT, ⁵University of Wisconsin Hospitals and Clinics, Madison, WI, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: The complement system has an important and underrecognized role in mediating tubulointerstitial disease in lupus nephritis (LN). The omics big data allows for identifying…
Abstract Number: 1636 • ACR Convergence 2022
Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort
Murray Urowitz¹, Mary E. Georgiou², Jiandong Su³, Anne MacKinnon³, Yulia Green⁴, Kerry Gairy², Roger A Levy⁵ and Patricia C. Juliao⁶, ¹University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ²GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ³University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Division of Rheumatology, Toronto, ON, Canada, ⁴GlaxoSmithKline, Clinical Development, Brentford, United Kingdom, ⁵GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁶GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA
Background/Purpose: Approximately 40% of adult patients with SLE develop LN, which can lead to end-stage kidney disease (ESKD).1 Renal response is used in clinical trials…
Abstract Number: 2082 • ACR Convergence 2022
A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy
Dario Roccatello¹, Savino Sciascia², Carla Naretto¹, Mirella Alpa¹, Roberta Fenoglio¹, Michela Ferro¹, Giacomo Quattrocchio¹, Elena Rubini¹, Elnaz Rahbani¹, Vittorio Modena¹ and Daniela Rossi¹, ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: We aimed to investigate the safety and efficacy of an intensified B-cell depletion induction therapy (IBCDT) without immunosuppressive maintenance regimen compared with standard of…
Abstract Number: 0324 • ACR Convergence 2021
Machine Learning: Identifying Lupus Nephritis Within Systemic Lupus Erythematosus in the Real World
Bruno Teixeira, David Bell, Tim Holbrook and Ben Hoskin, Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Around 40-70% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN). LN is often underdiagnosed and early diagnosis is crucial for reducing…
Abstract Number: 0769 • ACR Convergence 2021
Renal Outcomes in 1528 Childhood-onset Systemic Lupus Erythematosus Patients: A Brazilian Multicenter Study
Ana Paula Sakamoto¹, Clovis Silva², Aline Islabão³, Glaucia Novak², Beatriz Molinari², Rosa Pereira⁴, Claudia Saad-Magalhães⁵, Gleice Clemente⁶, Daniela Petry Pioto⁷, Nadia Aikawa⁴, Ana Pita², Vitor Trindade², Simone Appenzeller⁸, Luciana Carvalho⁹, Carlos Rabelo-Junior¹⁰, Adriana Fonseca¹¹, Flavio Sztajnbok¹², Maria Santos¹³, Blanca Elena Rios Gomes Bica¹⁴, Evaldo Sena¹⁵, Ana Moraes¹⁶, Melissa Fraga⁶, Teresa Robazzi¹⁷, Paulo Spelling¹⁸, Iloite Scheibel¹⁹, Andre Cavalcanti²⁰, Erica Matos²¹, Luciano Guimarães²², Flavia Santos²³, Licia Maria Henrique Mota²⁴, Eloisa Bonfá⁴ and Maria Terreri²⁵, ¹Federal University of So Paulo (UNIFESP), São Paulo, Brazil, ²Pediatric Rheumatology Unit, Children’s Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit, Hospital da Criança de Brasília Jose Alencar, Brasilia, DF, Brazil, ⁴Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Division, São Paulo State University (UNESP) – Faculdade de Medicina de Botucatu, Botucatu, Botucatu, Brazil, ⁶Universidade Federal de São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, SP, Brazil, ⁸Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ⁹Pediatric Rheumatology Unit, Ribeirão Preto Medical School – University of São Paulo, Ribeirão Preto, SP, Brazil, ¹⁰Pediatric Rheumatology Unit, Hospital Geral de Fortaleza, Fortaleza, CE, Brazil, ¹¹Pediatric Rheumatology Unit, Rio de Janeiro Federal University (IPPMG-UFRJ), Rio de Janeiro, RJ, Brazil, ¹²UFRJ/UERJ, Rio de Janeiro, Brazil, ¹³Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil, ¹⁴Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵Pediatric Rheumatology Unit, Lauro Vanderley University Hospital, João Pessoa, PB, Brazil, ¹⁶Pediatric Rheumatology Unit, Federal University of Pará, Belém, PA, Brazil, ¹⁷Pediatric Rheumatology Unit, Federal University of Bahia, Salvador, BA, Brazil, ¹⁸Pediatric Rheumatology Unit, Hospital Evangélico de Curitiba, Curitiba, PR, Brazil, ¹⁹Pediatric Rheumatology Unit, Hospital Criança Conceição, Porto Alegre, RS, Brazil, ²⁰Pediatric Rheumatology Unit, Federal University of Pernambuco, Recife, PE, Brazil, ²¹Pediatric Rheumatology Unit, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil, ²²Pediatric Rheumatology Unit, University of Brasília, Brasilia, DF, Brazil, ²³Pediatric Rheumatology Unit, Federal University of Minas Gerais, Belo Horizonte, Belo Horizonte, MG, Brazil, ²⁴Universidade de Brasília, Brasilia, Brazil, ²⁵UNIFESP, São Paulo, Brazil
Background/Purpose: Lupus nephritis is a frequent manifestation in childhood-onset systemic lupus erythematosus (cSLE) and has a great potential for chronic kidney disease (CKD), requiring dialysis…
Abstract Number: 1460 • ACR Convergence 2021
Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry
Mayce Haj-Ali¹, Kristina Deonaraine², Alexis Engel³, Yingzhi Qian¹, Amit Saxena⁴, Peter Izmirly², Jill Buyon⁴ and H. Michael Belmont⁴, ¹NYU Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴NYU School of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) disproportionately affects racial and ethnic populations. Contreras reported African-American (AA) and Hispanic patients had worse outcomes as compared to patients of…
Abstract Number: 1754 • ACR Convergence 2021
Effect of Belimumab on Autoantibodies, Complement, and B-Cell Subsets in Patients with Lupus Nephritis
Brad Rovin¹, Richard Furie², Ana Malvar³, Cynthia Aranow⁴, Jose M Pego-Reigosa⁵, Elena Zakharova⁶, Andreas Schwarting⁷, Angela Jones-Leone⁸, Anuradha Madan⁸, Jennifer Gilbride⁹, David Roth⁸, Yulia Green⁹ and André van Maurik¹⁰, ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Hospital Fernandez, Buenos Aires, Argentina, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵Complexo Hospitalario Universitario de Vigo, Hospital Meixoeiro, Galicia Sur Health Research Institute, Rheumatology Department and IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Vigo, Spain, ⁶Moscow City Clinical Hospital n.a. S.P. Botkin, Moscow, Russia, ⁷University Center of Autoimmunity, Mainz, Germany, ⁸GlaxoSmithKline, Collegeville, PA, ⁹GlaxoSmithKline, Brentford, United Kingdom, ¹⁰GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Lupus nephritis (LN) is a complication affecting ~40% of patients with systemic lupus erythematosus (SLE). Belimumab (BEL), an anti–B-lymphocyte stimulator therapy, was approved in…
Abstract Number: 0326 • ACR Convergence 2021
Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations
Michelle Petri¹, Romy Kallas², Jessica Li³, Laurence Magder⁴ and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Lankenau Medical Center, Lankenau, PA, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: The APOL1 gene is implicated in induction of TLR3 agonists and interferons as well as in autophagy. Two genetic variants, G1 (2 single nucleotide…
Abstract Number: 0784 • ACR Convergence 2021
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus in North America
Laura Cannon¹, Scott Wenderfer², Laura Lewandowski³, Jennifer Cooper⁴, Beatrice Goilav⁵, Andrea Knight⁶, Aimee Hersh⁷, Stacy Ardoin⁸ and Rebecca Sadun¹, ¹Duke University, Durham, NC, ²Baylor College of Medicine, Houston, TX, ³NIAMS, NIH, Rockville, MD, ⁴University of Colorado/Children's Hospital Colorado, Denver, CO, ⁵Children's Hospital at Montefiore, Bronx, NY, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷University of Utah, Salt Lake City, UT, ⁸Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) has higher rates of lupus nephritis (LN) than adult-onset SLE, often requiring intensive immunosuppression. This study examined North American…
Abstract Number: 1461 • ACR Convergence 2021
Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis
Richard Furie¹, Frédéric Houssiau², Liz Lightstone³, Xueqing Yu⁴, Julia Weinmann-Menke⁵, Yoshiya Tanaka⁶, Angela Jones-Leone⁷, Tania Gonzalez-Rivera⁷, Jennifer Gilbride⁸, Anuradha Madan⁷, Yulia Green⁸ and David Roth⁷, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium, ³Department of Immunology and Inflammation, Imperial College, London, United Kingdom, ⁴Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (People's Republic), ⁵University Hospital Mainz, Mainz, Germany, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷GlaxoSmithKline, Collegeville, PA, ⁸GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose: In the BLISS-LN trial (GSK Study BEL114054; NCT01639339), the administration of belimumab (BEL), a B-lymphocyte stimulator antagonist, resulted in improved renal outcomes in patients…
Abstract Number: 1756 • ACR Convergence 2021
Class V Systemic Lupus Erythematosus Nephritis Patients Are Undertreated and Face Similar Adverse Renal Outcomes as Class III/IV Patients
April Barnado and Alex Camai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Few studies have investigated treatment patterns and renal outcomes in class V systemic lupus erythematosus (SLE) nephritis patients compared to class III/IV patients. Prior…
Abstract Number: 0328 • ACR Convergence 2021
Natural Language Processing to Identify Lupus Nephritis Phenotype in Electronic Health Records
Yu Deng¹, Jennifer Pacheco¹, Anh Chung¹, Chengsheng Mao¹, Joshua Smith², juan zhao¹, Wei-Qi Wei², April Barnado³, Chunhua Weng⁴, Cong Liu⁴, Adam Gordon¹, Jingzhi Yu¹, Yacob Tedla¹, Abel Kho¹, Rosalind Ramsey-Goldman¹, Theresa Walunas¹ and Yuan Luo¹, ¹Northwestern University, Chicago, IL, ²Vanderbilt Universty Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Columbia University, New York, NY
Background/Purpose: Lupus nephritis (LN) is a major disease manifestation of Systemic lupus erythematosus (SLE) leading to organ damage and increased mortality. Accurately identifying lupus nephritis…
Abstract Number: 0874 • ACR Convergence 2021
Serum Galectin-9 and CXCL-10 but Not Their Urinary Levels Reflect Lupus Activity
Pankti Mehta, Pratibha Singh and Amita Aggarwal, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: SLE is characterized by increased type I IFN signature in the blood and immune cells. Traditionally, type I IFN signature is measured by gene…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.